PDF下载 ( 2941 KB)
Clinical practice guidelines for the interventional treatment of advanced pancreatic carcinoma (on trial) (6th edition)
-
TNM分期 内容 TNM分期 T分期 N分期 M分期 原发肿瘤(T) Tx：原发肿瘤无法评估
T0：无原发肿瘤证据
Tis：原位癌
T1: 肿瘤最大径≤2.0 cm
T1a：肿瘤最大径≤0.5 cm
T1b: 肿瘤最大径＞0.5 cm且＜1.0 cm
T1c：肿瘤最大径≥1.0 cm且≤2.0 cm
T2: 肿瘤最大径＞2.0 cm且≤4.0 cm
T3: 肿瘤最大径＞4.0 cm
T4: 肿瘤不论大小，累及腹腔干、
肠系膜上动脉，和/或肝总动脉0 Tis N0 M0 ⅠA T1 N0 M0 ⅠB T2 N0 M0 ⅡA T3 N0 M0 ⅡB T1~3 N1 M0 Ⅲ T4 Any N M0 Any T N2 M0 Ⅳ Any T Any N M1 区域淋巴结(N) Nx: 区域淋巴结无法评估
N0: 无区域淋巴结转移
N1: 1~3枚区域淋巴结转移
N2: 4枚以上区域淋巴结转移远处转移(M) M0: 无远处转移M1: 有远处转移 
下载: 导出CSV
表 2 射频参量及相关参数
Table 2. RF parameters and related parameters
电极种类 数量 间距(mm) 目标能量(kJ) 功率设定(W) 治疗长度(mm) 治疗直径(mm) 治疗体积(cm3) T20 1 9 20 22 20 5 T20 2 7 14 40 25 20~27 7 T20 3 15 24 60 25 20~30 12 T30 1 15 30 32 22 5.5 T30 2 13 25 60 35 25 8 T30 3 15 15~35 90 35 20~30 14 T40 1 29 40 44 25 14 T40 2 13.3 39 80 45 25~33 19 T40 3 20 35~70 120 50 30~40 22 T40 3 25 70~130 120 55 40~50 47 T40 3 30 130~250 120 60 50~60 87
下载: 导出CSV
表 3 微波能量及相关参数
Table 3. Microwave energy and related parameters
消融时间 主机功率 50 W 55 W 60 W 70 W 5 min 40×25×5 40×26×5 42×27×6 44×30×7 8 min 42×26×5 43×27×6 44×30×6 46×32×7 10 min 45×28×5 48×30×6 49×32×7 50×34×8 12 min 48×30×6 49×32×7 50×34×7 52×36×10 15 min 50×34×6 51×36×7 52×38×7 54×40×10
下载: 导出CSV
表 4 晚期胰腺癌介入方法选择方案
Table 4. Selection of interventional methods for advanced pancreatic cancer
cTAI治疗 低/未分化腺癌、血供丰富、基因敏感ROBO3↑/miR-250b↓等 胰头部：胃十二指肠动脉、肠系膜上动脉 胰体尾部：脾短动脉、胃网膜右动脉 优势动脉：化疗栓塞；非优势动脉：栓塞 物理治疗 中/高分化腺癌、血供不丰富、基因不敏感ROBO3/miR-250b等 胰头部：125I粒子植入 体尾部：射频/微波消融
下载: 导出CSV
表 5 三组晚期胰腺癌患者基本资料
Table 5. Basic data of three groups of patients with advanced pancreatic cancer
参数 对症治疗(n=406) 对症+介入(n=422) 对症+化疗(n=190) 统计值 P值 年龄(岁) 71.84±11.58 66.39±11.37 62.25±10.05 F=1.290 0.075 性别[例(%)] χ2=0.955 0.620 男 252(62.07) 255(60.43) 110(57.89) 女 154(37.93) 167(39.57) 80(42.11) TNM分期[例(%)] χ2=2.012 0.366 T3N1MO 55(13.55) 45(10.66) 20(10.53) T3N1M1 351(86.45) 377(89.34) 170(89.47) 肿瘤大小[例(%)] χ2=8.753 0.068 ＜3.0 cm 10(2.46) 9(2.13) 8(4.21) 3.0~5.0 cm 38(9.36) 50(11.85) 31(16.31) ＞5.0 cm 358(88.18) 363(86.02) 151(79.48) 有无转移[例(%)] χ2=0.075 0.963 有 345(84.98) 360(85.31) 152(80.00) 无 61(15.02) 62(14.69) 38(20.00) 腹腔积液[例(%)] χ2=25.823 0.000 有 80(19.70) 32(7.58) 28(14.74) 无 326(80.30) 390(92.42) 162(85.26) 黄疸[例(%)] χ2=83.009 0.000 有 122(30.05) 250(59.24) 110(57.89) 无 284(69.95) 172(40.76) 80(42.11) Child-Pugh分级[例(%)] χ2=72.295 0.000 A级 16(3.94) 8(1.90) 35(18.42) B级 94(23.15) 105(24.88) 48(25.26) C级 296(72.90) 309(73.22) 107(56.32) CA19-9[例(%)] χ2=3.355 0.187 正常 88(21.67) 105(24.88) 54(28.42) 异常 318(78.33) 317(75.12) 136(71.58)
下载: 导出CSV
表 6 三组临床缓解率比较
Table 6. Comparison of clinical remission rates among the three groups
mRECIST 对症治疗(n=406) 对症+介入(n=422) 对症+化疗(n=190) 总计(n=1018) P值 完全缓解+部分缓解[例(%)] 80(19.7) 198(46.9) 79(41.6) 341(33.5) 0.000 疾病稳定[例(%)] 105(25.9) 147(34.8) 59(31.1) 418(41.1) 疾病进展[例(%)] 221(54.4) 77(18.2) 55(28.9) 259(25.4)
下载: 导出CSV
表 7 三组间6、12、18个月生存率比较
Table 7. Comparison of 6, 12 and 18 month survival rates among the three groups
时间 结局 对症治疗(n=406) 对症+介入(n=422) 对症+化疗(n=190) 总计(n=1018) P值 6个月 0.000 存活[例(%)] 77(19.0) 341(80.8) 120(63.2) 538(52.8) 死亡[例(%)] 329(81.0) 81(19.2) 70(36.8) 480(47.2) 12个月 0.000 存活[例(%)] 8(2.0) 114(27.0) 42(22.1) 164(16.1) 死亡[例(%)] 398(98.0) 308(73.0) 148(77.9) 854(83.9) 18个月 0.000 存活[例(%)] 0 46(10.9) 15(7.9) 61(6.0) 死亡[例(%)] 406(100.0) 376(89.1) 175(92.1) 957(94.0)
下载: 导出CSV
-
[1] International Agency for Research on Cancer, World Health Organization. Global cancer observatory 2018[DB/OL]. http://gco.iarc.fr/. [2] CABASAG CJ, FERLAY J, LAVERSANNE M, et al. Pancreatic cancer: an increasing global public health concern[J]. Gut, 2021. DOI: 10.1136/gutjnl-2021-326311. [3] ALLEN PJ, KUK D, CASTILLO CF, et al. Multi-institutional validation study of the american joint commission on cancer (8th edition) changes for T and N staging in patients with pancreatic adenocarcinoma[J]. Ann Surg, 2017, 265(1): 185-191. DOI: 10.1097/SLA.0000000000001763. [4] SOBIN LH, GOSPODAROWICZ MK, WITTEKIND C, et al. TNM classification of malignant tumours[M]. 7th ed. Chichester, West Sussex, UK; Hoboken, NJ: Wiley-Blackwell, 2010. [5] KRUGER S, SCHIRLE K, HAAS M, et al. Prolonged time to treatment initiation in advanced pancreatic cancer patients has no major effect on treatment outcome: a retrospective cohort study controlled for lead time bias and waiting time paradox[J]. J Cancer Res Clin Oncol, 2020, 146(2): 391-399. DOI: 10.1007/s00432-019-03061-4. [6] HIDAGOM M. Pancreatic cancer[J]. N Engl J Med, 2010, 362(17): 1605-1617. DOI: 10.1056/NEJMra0901557 [7] HEINRICH S, KRAFT D, STAIB-SEBLER E, et al. Phase Ⅱ study on combined intravenous and intra-arterial chemotherapy with gemcitabine and mitomycin C in patients with advanced pancreatic cancer[J]. Hepatogastroenterology, 2013, 60(126): 1492-1496. DOI: 10.5754/hge11805. [8] Pancreatic Cancer Committee of Chinese Anti-Cancer Association. Comprehensive guidelines for the diagnosis and treatment of pancreatic cancer (2018 version)[J]. J Clin Hepatol, 2018, 34(10): 2109-2120. DOI: 10.3969/j.issn.1001-5256.2018.10.011.中国抗癌协会胰腺癌专业委员会. 胰腺癌综合诊治指南(2018版)[J]. 临床肝胆病杂志, 2018, 34(10): 2109-2120. DOI: 10.3969/j.issn.1001-5256.2018.10.011. [9] Pancreatic Surgery Group, Branch of Surgery, Chinese Medical Association, Editorial Department of Chinese Journal of Surgery. Expert consensus on prevention and treatment of common surgical complications after pancreatic surgery (2010)[J]. Chin J Surg, 2010, 48(18): 1365-1368. DOI: 10.3760/cma.j.issn.0529-5815.2010.18.002.中华医学会外科学分会胰腺外科学组, 中华外科杂志编辑部. 胰腺术后外科常见并发症预防及治疗的专家共识(2010)[J]. 中华外科杂志, 2010, 48(18): 1365-1368. DOI: 10.3760/cma.j.issn.0529-5815.2010.18.002. [10] NI XQ, YU XR, LIU L. Clinical diagnostic criteria for pancreatic cancer in China[J]. China Oncol, 2012, 22(2): 81-87. DOI: 10.3969/j.issn.1007-3969.2012.02.001.倪泉兴, 虞先濬, 刘亮. 中国胰腺癌临床诊断标准的探讨[J]. 中国癌症杂志, 2012, 22(2): 81-87. DOI: 10.3969/j.issn.1007-3969.2012.02.001. [11] ARCELLI A, GUIDO A, BUWENGE M, et al. Higher biologically effective dose predicts survival in SBRT of pancreatic cancer: a multicentric analysis (PAULA-1)[J]. Anticancer Res, 2020, 40(1): 465-472. DOI: 10.21873/anticanres.13975. [12] SUKER M, NUYTTENS JJ, ESKENS F, et al. Efficacy and feasibility of stereotactic radiotherapy after folfirinox in patients with locally advanced pancreatic cancer (LAPC-1 trial)[J]. E Clinical Medicine, 2019, 17: 100200. DOI: 10.1016/j.eclinm.2019.10.013. [13] KIRTLAND HB Jr. A safe method of pancreatic biopsy; a preliminary report[J]. Am J Surg, 1951, 82(4): 451-457. DOI: 10.1016/0002-9610(51)90372-8. [14] SMITH EH, BARTRUM RJ Jr, CHANG YC. Ultrasonically guided percutaneous aspiration biopsy of the pancreas[J]. Radiology, 1974, 112(3): 737-738. DOI: 10.1148/112.3.737. [15] LVNING M, KURSAWE R, SCHÖPKE W, et al. CT guided percutaneous fine-needle biopsy of the pancreas[J]. Eur J Radiol, 1985, 5(2): 104-108. [16] DELMASCHIO A, VANZULLI A, SIRONI S, et al. Pancreatic cancer versus chronic pancreatitis: diagnosis with CA 19-9 assessment, US, CT, and CT-guided fine-needle biopsy[J]. Radiology, 1991, 178(1): 95-99. DOI: 10.1148/radiology.178.1.1984331. [17] ZECH CJ, HELMBERGER T, WICHMANN MW, et al. Large core biopsy of the pancreas under CT fluoroscopy control: results and complications[J]. J Comput Assist Tomogr, 2002, 26(5): 743-749. DOI: 10.1097/00004728-200209000-00014. [18] KLASSEN DK, WEIR MR, CANGRO CB, et al. Pancreas allograft biopsy: safety of percutaneous biopsy-results of a large experience[J]. Transplantation, 2002, 73(4): 553-555. DOI: 10.1097/00007890-200202270-00011. [19] SYED A, BABICH O, RAO B, et al. Endoscopic ultrasound guided fine-needle aspiration vs core needle biopsy for solid pancreatic lesions: Comparison of diagnostic accuracy and procedural efficiency[J]. Diagn Cytopathol, 2019, 47(11): 1138-1144. DOI: 10.1002/dc.24277. [20] D'ONOFRIO M, MALAGÒ R, ZAMBONI G, et al. Ultrasonography of the pancreas. 5. Interventional procedures[J]. Abdom Imaging, 2007, 32(2): 182-190. DOI: 10.1007/s00261-006-9011-5. [21] RAYMOND S, YUGAWA D, CHANG K, et al. Metastatic neoplasms to the pancreas diagnosed by fine-needle aspiration/biopsy cytology: A 15-year retrospective analysis[J]. Diagn Cytopathol, 2017, 45(9): 771-783. DOI: 10.1002/dc.23752. [22] National Comprehensive Cancer Network. NCCN guidelines for pancreatic adenocarcinoma[DB/OL]. https://www.nccn.org/professionals/physician_gls/default.aspx#pancreatic. [23] MOULLA Y, PETERSEN TO, MAIWALD B, et al. Ablative treatment options for locally advanced unresectable and borderline resectable pancreatic carcinoma[J]. Chirurg, 2020, 91(4): 319-328. DOI: 10.1007/s00104-019-01072-y. [24] UYANIK SA, ÖǦÜŞLÜ U, YILMAZ B, et al. Percutaneous intraductal microwave ablation of malignant biliary strictures: initial experience[J]. AJR Am J Roentgenol, 2020, 215(3): 753-759. DOI: 10.2214/AJR.19.21897. [25] YANG SY, LIU F, LIU Y, et al. Stent insertion with high-intensity focused ultrasound ablation for distal biliary obstruction secondary to pancreatic carcinoma[J]. Medicine (Baltimore), 2020, 99(6): e19099. DOI: 10.1097/MD.0000000000019099. [26] HE XF, XIAO YY, ZHANG X, et al. Preliminary clinical application of the robot-assisted CT-guided irreversible electroporation ablation for the treatment of pancreatic head carcinoma[J]. Int J Med Robot, 2020, 16(4): e2099. DOI: 10.1002/rcs.2099. [27] FEI Q, PAN Y, LIN W, et al. High-dimensional single-cell analysis delineates radiofrequency ablation induced immune microenvironmental remodeling in pancreatic cancer[J]. Cell Death Dis, 2020, 11(7): 589. DOI: 10.1038/s41419-020-02787-1. [28] SONG HB. Possible involvement of HSP70 in pancreatic cancer cell proliferation after heat exposure and impact on RFA postoperative patient prognosis[J]. Biochem Biophys Rep, 2019, 20: 100700. DOI: 10.1016/j.bbrep.2019.100700. [29] TONGUC T, STRUNK H, GONZALEZ-CARMONA MA, et al. US-guided high-intensity focused ultrasound (HIFU) of abdominal tumors: outcome, early ablation-related laboratory changes and inflammatory reaction. A single-center experience from Germany[J]. Int J Hyperthermia, 2021, 38(2): 65-74. DOI: 10.1080/02656736.2021.1900926. [30] TONGUC T, STRUNK H, GONZALEZ-CARMONA MA, et al. US-guided high-intensity focused ultrasound (HIFU) of abdominal tumors: outcome, early ablation-related laboratory changes and inflammatory reaction. A single-center experience from Germany[J]. Int J Hyperthermia, 2021, 38(2): 65-74. DOI: 10.1080/02656736.2021.1900926. [31] FILIPPIADIS D, PTOHIS N, EFTHYMIOU E, et al. A Technical report on the performance of percutaneous cryoneurolysis of splanchnic nerves for the treatment of refractory abdominal pain in patients with pancreatic cancer: initial experience[J]. Cardiovasc Intervent Radiol, 2021, 44(5): 789-794. DOI: 10.1007/s00270-020-02756-3. [32] XIN Y, YANG Y, CHEN Y, et al. Safety and efficacy of ultrasound-guided percutaneous coaxial core biopsy of pancreatic lesions: a retrospective study[J]. J Ultrasound, 2021, 24(3): 269-277. DOI: 10.1007/s40477-020-00487-2. [33] LACOMB JF, PLENKER D, TIRIAC H, et al. Single-pass vs 2-pass endoscopic ultrasound-guided fine-needle biopsy sample collection for creation of pancreatic adenocarcinoma organoids[J]. Clin Gastroenterol Hepatol, 2021, 19(4): 845-847. DOI: 10.1016/j.cgh.2020.02.045. [34] DING D, JAVED AA, CUNNINGHAM D, et al. Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017[J]. Cancer Lett, 2021, 497: 221-228. DOI: 10.1016/j.canlet.2020.10.039. [35] SHI HB, YANG MJ, WANG XL, et al. Feeding arteries of advanced pancreatic cancer: evaluation of 218 patients by digital subtract angiography[J]. Chin J Clinl Med, 2014, 21(1): 61-62. https://www.cnki.com.cn/Article/CJFDTOTAL-LCYX201401023.htm施惠斌, 杨敏捷, 王小林, 等. 晚期胰腺癌患者的肿瘤血供来源: 218例患者的DSA评价[J]. 中国临床医学, 2014, 21(1): 61-62. https://www.cnki.com.cn/Article/CJFDTOTAL-LCYX201401023.htm [36] DAOUD AZ, MULHOLLAND EJ, COLE G, et al. MicroRNAs in Pancreatic Cancer: biomarkers, prognostic, and therapeutic modulators[J]. BMC Cancer, 2019, 19(1): 1130. DOI: 10.1186/s12885-019-6284-y. [37] RUARUS A, VROOMEN L, PUIJK R, et al. Locally advanced pancreatic cancer: a review of local ablative therapies[J]. Cancers (Basel), 2018, 10(1): 16. DOI: 10.3390/cancers10010016. [38] HESS V, GLIMELIUS B, GRAWE P, et al. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial[J]. Lancet Oncol, 2008, 9(2): 132-138. DOI: 10.1016/S1470-2045(08)70001-9. [39] MAITHEL SK, MALONEY S, WINSTON C, et al. Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma[J]. Ann Surg Oncol, 2008, 15(12): 3512-3520. DOI: 10.1245/s10434-008-0134-5. [40] TAKAHASHI H, OHIGASHI H, ISHIKAWA O, et al. Serum CA19-9 alterations during preoperative gemcitabine-based chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival[J]. Ann Surg, 2010, 251(3): 461-469. DOI: 10.1097/SLA.0b013e3181cc90a3. [41] GOONETILLEKE KS, SIRIWARDENA AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer[J]. Eur J Surg Oncol, 2007, 33(3): 266-270. DOI: 10.1016/j.ejso.2006.10.004. [42] TEMPERO MA, MALAFA MP, AL-HAWARY M, et al. Pancreatic adenocarcinoma, version 2. 2017, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2017, 15: 1028-1061. DOI: 10.6004/jnccn.2017.0131. [43] NIMURA Y, NAGINO M, TAKAO S, et al. Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas: long-term results of a Japanese multicenter randomized controlled trial[J]. J Hepatobiliary Pancreat Sci, 2012, 19(3): 230-241. DOI: 10.1007/s00534-011-0466-6. [44] JANG JY, KANG MJ, HEO JS, et al. A prospective randomized controlled study comparing outcomes of standard resection and extended resection, including dissection of the nerve plexus and various lymph nodes, in patients with pancreatic head cancer[J]. Ann Surg, 2014, 259(4): 656-664. DOI: 10.1097/SLA.0000000000000384. [45] SIEGEL R, MA J, ZOU Z, et al. Cancer statistics, 2014[J]. CA Cancer J Clin, 2014, 64(1): 9-29. DOI: 10.3322/caac.21208. [46] National Cancer Network. Clinical practice guidelines in oncology. pancreatic adenocarcinoma. version 2.2014[DB/OL]. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. [47] TOL JA, GOUMA DJ, BASSI C, et al. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS)[J]. Surgery, 2014, 156(3): 591-600. DOI: 10.1016/j.surg.2014.06.016. [48] BOCKHORN M, UZUNOGLU FG, ADHAM M, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS)[J]. Surgery, 2014, 155(6): 977-988. DOI: 10.1016/j.surg.2014.02.001. [49] HARTWIG W, VOLLMER CM, FINGERHUT A, et al. Extended pancreatectomy in pancreatic ductal adenocarcinoma: definition and consensus of the International Study Group for Pancreatic Surgery (ISGPS)[J]. Surgery, 2014, 156(1): 1-14. DOI: 10.1016/j.surg.2014.02.009. [50] ASBUN HJ, CONLON K, FERNANDEZ-CRUZ L, et al. When to performance pancreatoduodenectomy in the absence of positive histology? A consensus statement by the International Study Group of Pancreatic Surgery[J]. Surgery, 2014, 155(5): 887-892. DOI: 10.1016/j.surg.2013.12.032. [51] GRECO SH, AUGUST DA, SHAH MM, et al. Neoadjuvant therapy is associated with lower margin positivity rates after Pancreaticoduodenectomy in T1 and T2 pancreatic head cancers: An analysis of the National Cancer Database[J]. Surg Open Sci, 2021, 3: 22-28. DOI: 10.1016/j.sopen.2020.12.001. [52] BLOMSTRAND H, GREEN H, FREDRIKSON M, et al. Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel[J]. BMC Cancer, 2020, 20(1): 950. DOI: 10.1186/s12885-020-07426-8. [53] Interventional Group, Radiology Branch, Chinese Medical Association. Guide to intra-arterial infusion chemotherapy for pancreatic cancers (draft text)[J]. J Intervent Radiol, 2012, 21(5): 353-355. DOI: 10.3969/j.issn.1008-794X.2012.05.001.中华医学会放射学分会介入学组. 胰腺癌经动脉灌注化疗指南(草案)[J]. 介入放射学杂志, 2012, 21(5): 353-355. DOI: 10.3969/j.issn.1008-794X.2012.05.001. [54] Japan Pancreas Society. Classification of pancreatic carcinoma[M]. Second English ed. Tokyo: Kanehara & Co., Ltd., 2003. [55] PHILIP PA, BENEDETTI J, CORLESS CL, et al. Phase Ⅲ study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205[J]. J Clin Oncol, 2010, 28(22): 3605-3610. DOI: 10.1200/JCO.2009.25.7550. [56] KINDLER HL, NIEDZWIECKI D, HOLLIS D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase Ⅲ trial of the Cancer and Leukemia Group B (CALGB 80303)[J]. J Clin Oncol, 2010, 28(22): 3617-3622. DOI: 10.1200/JCO.2010.28.1386. [57] MOORE MJ, GOLDSTEIN D, HAMM J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase Ⅲ trial of the National Cancer Institute of Canada Clinical Trials Group[J]. J Clin Oncol, 2007, 25(15): 1960-1966. DOI: 10.1200/JCO.2006.07.9525. [58] 58. TANAKA T, SAKAGUCHI H, SHO M, et al. A novel interventional radiology technique for arterial infusion chemotherapy against advanced pancreatic cancer[J]. AJR Am J Roentgenol, 2009, 192(4): W168-W177. DOI: 10.2214/AJR.08.1392. [59] CONROY T, DESSEIGNE F, YCHOU M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer[J]. N Engl J Med, 2011, 364(19): 1817-1825. DOI: 10.1056/NEJMoa1011923. [60] KULKE MH, TEMPERO MA, NIEDZWIECKI D, et al. Randomized phase Ⅱ study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904[J]. J Clin Oncol, 2009, 27(33): 5506-5512. DOI: 10.1200/JCO.2009.22.1309. [61] CUNNINGHAM D, CHAU I, STOCKEN DD, et al. Phase Ⅲ randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer[J]. J Clin Oncol, 2009, 27(33): 5513-5518. DOI: 10.1200/JCO.2009.24.2446. [62] LOUVET C, LABIANCA R, HAMMEL P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase Ⅲ trial[J]. J Clin Oncol, 2005, 23(15): 3509-3516. DOI: 10.1200/JCO.2005.06.023. [63] OETTLE H, RICHARDS D, RAMANATHAN RK, et al. A phase Ⅲ trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer[J]. Ann Oncol, 2005, 16(10): 1639-1645. DOI: 10.1093/annonc/mdi309. [64] ABOU-ALFA GK, LETOURNEAU R, HARKER G, et al. Randomized phase Ⅲ study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer[J]. J Clin Oncol, 2006, 24(27): 4441-4447. DOI: 10.1200/JCO.2006.07.0201. [65] TEMPERO M, PLUNKETT W, RUIZ VAN HAPEREN V, et al. Randomized phase Ⅱ comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma[J]. J Clin Oncol, 2003, 21(18): 3402-3408. DOI: 10.1200/JCO.2003.09.140. [66] MENON KV, GOMEZ D, SMITH AM, et al. Impact of margin status on survival following pancreatoduo-denectomy for cancer: the Leeds Pathology Protocol (LEEPP)[J]. HPB(Oxford), 2009, 11(1): 18-24. DOI: 10.1111/j.1477-2574.2008.00013.x. [67] WANG JJ, ZHANG FJ. Tumor radioactive particle therapy specification[M]. Beijing: People's Health Publishing House, 2016.王俊杰, 张福君. 肿瘤放射性粒子治疗规范[M]. 北京: 人民卫生出版社, 2016. [68] WANG CF, ZHAO P, LI YX, et al. Role of 125I seed implantation in treatment of unresectable pancreatic cancer[J]. Natl Med J China, 2012, 90(2): 92-95. DOI: 10.3760/cma.j.issn.0376-2491.2010.02.007.王成锋, 赵平, 李晔雄, 等. 125I粒子植入治疗局部进展期胰腺癌[J]. 中华医学杂志, 2012, 90(2): 92-95. DOI: 10.3760/cma.j.issn.0376-2491.2010.02.007. [69] FUJⅡ T, SATOI S, YAMADA S, et al. Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting[J]. J Gastroenterol, 2017, 52(1): 81-93. DOI: 10.1007/s00535-016-1217-x. [70] LUNDIN J, ROBERTS PJ, KUUSELA P, et al. Prognostic significance of serum CA242 in pancreatic cancer. A comparison with CA19-9[J]. Anticancer Res, 1995, 15(5): 2181-2186. [71] MA J, LUO J, GU J, et al. Malignant obstructive jaundice treated with intraluminal placement of Iodine-125 seed strands and metal stents: An analysis of long-term outcomes and prognostic features[J]. Brachytherapy, 2018, 17(4): 689-695. DOI: 10.1016/j.brachy.2018.04.001. [72] YANG M, YAN Z, LUO J, et al. A pilot study of intraluminal brachytherapy using 125I seed strand for locally advanced pancreatic ductal adenocarcinoma with obstructive jaundice[J]. Brachytherapy, 2016, 15(6): 859-864. DOI: 10.1016/j.brachy.2016.05.004. [73] YU BF. Intratumoral injection of alcohol saturated solution of anticancer drugs and its pharmacokinetics — a new concept of tumor self therapeutic coagulation block as sustained-release Library of anticancer drugs[J]. Chin J Cancer Prev Treat, 1994, 2: 97-100. https://www.cnki.com.cn/Article/CJFDTOTAL-QLZL402.006.htm于保法. 抗癌药物酒精饱和液肿瘤内注射疗法及其药物动力学研究——一种肿瘤自身治疗性凝固块作为抗癌药物缓释库的新概念[J]. 中华肿瘤防治杂志, 1994, 2: 97-100. https://www.cnki.com.cn/Article/CJFDTOTAL-QLZL402.006.htm [74] Committee of Experts on Radioactive Particle Implantation Technology, Chinese Medical Doctor Association; Particle Treatment Branch, Committee of Minimally Invasive Therapy in Oncology, Chinese Anti-cancer Association. Chinese expert consensus on treatment of pancreatic cancer by radioactive 125I particle implantation (2017)[J]. J Clin Hepatol, 2018, 34(4): 716-723. DOI: 10.3969/j.issn.1001-5256.2018.04.007.中国医师协会放射性粒子植入技术专家委员会, 中国抗癌协会肿瘤微创治疗专业委员会粒子治疗分会. 放射性125I粒子植入治疗胰腺癌中国专家共识(2017年版)[J]. 临床肝胆病杂志, 2018, 34(4): 716-723. DOI: 10.3969/j.issn.1001-5256.2018.04.007. [75] ZHU HD, GUO JH, HUANG MH, et al. Irradiation stents vs. conventional metal stents for unresectable malignant biliary obstruction: A multicenter trial[J]. J Hepatol, 2018, 68(5): 970-977. DOI: 10.1016/j.jhep.2017.12.028. [76] BU JQ, YU BF. Slow intra-tumor release of drugs on B16 melonoma in mice[J]. J Shandong Univ (Health Sciences), 2007, 45(10): 988-991. DOI: 10.3969/j.issn.1671-7554.2007.10.005.卜洁琼, 于保法. 瘤内缓释治疗对B16黑色素瘤小鼠影响的实验研究[J]. 山东大学学报(医学版), 2007, 45(10): 988-991. DOI: 10.3969/j.issn.1671-7554.2007.10.005. [77] YU BF. Tumor interventional chemoimmunotherapy[M]. Beijing: Military Medical Press, 2014.于保法. 肿瘤介入化学免疫治疗学[M]. 北京: 军事医学出版社, 2014. [78] CAI P, CHEN GM, YANG XG, et al. Clinical efficacy of local hyperthermia in the treatment of advanced pancreatic cancer[J]. Mod Oncol, 2015, 23(5): 655-657. DOI: 10.3969/j.issn.1672-4992.2015.05.23.蔡鹏, 陈桂明, 杨先国, 等. 局部热疗联合化疗治疗晚期胰腺癌的疗效观察[J]. 现代肿瘤医学, 2015, 23(5): 655-657. DOI: 10.3969/j.issn.1672-4992.2015.05.23. [79] ZONG Y, NI SX, ZHANG XQ. Clinical analysis of oxaliplatin treatment for the advanced pancreatic cancer through regional arterial infusion chemotherapy[J]. Pract Pharm Clin Remedies, 2013, 16(4): 284-285. DOI: 10.3969/j.issn.1673-0070.2013.04.006.宗煜, 倪绍祥, 张宪庆. 奥沙利铂经区域性动脉灌注化疗治疗晚期胰腺癌临床分析[J]. 实用药物与临床, 2013, 16(4): 284-285. DOI: 10.3969/j.issn.1673-0070.2013.04.006. [80] REN XH, LIU L, LIU PP, et al. Changes of T lymphocyte subgroups in cancer patients and its relationship with tumor staging[J]. J Third Milit Med Univ, 2006, 28(18): 1906-1908. DOI: 10.3321/j.issn:1000-5404.2006.18.024.任秀红, 刘莉, 刘平平, 等. 恶性肿瘤患者T细胞亚群变化及其与肿瘤分期的关系[J]. 第三军医大学学报, 2006, 28(18): 1906-1908. DOI: 10.3321/j.issn:1000-5404.2006.18.024. [81] BALZANO G, DI CARLO V. Is CA 19-9 useful in the management of pancreatic cancer?[J]. Lancet Oncol, 2008, 9(2): 89-91. DOI: 10.1016/S1470-2045(08)70011-1. [82] HAN S, CAO C, TANG T, et al. ROBO3 promotes growth and metastasis of pancreatic carcinoma[J]. Cancer Lett, 2015, 366(1): 61-70. DOI: 10.1016/j.canlet.2015.06.004. [83] LIU T, WU G, CHENG J, et al. Multifunctional lymph-targeted platform based on Mn@ mSiO2 nanocomposites: Combining PFOB for dual-mode imaging and DOX for cancer diagnose and treatment[J]. Nano Research, 2016, 9: 473-489. DOI: 10.1007/s12274-015-0929-1 [84] LIU LX, JI W, WANG JH, et al. A retrospective analysis of patients with unresectable pancreatic cancer treated with combined transarterial intervention and three dimensional conformal radiotherapy[J]. China Oncol, 2011, 21(1): 46-51. DOI: 10.3969/j.issn.1007-3969.2011.01.009.刘凌晓, 姬巍, 王建华, 等. 介入治疗联合三维适形放疗治疗不能手术切除的胰腺癌患者疗效分析[J]. 中国癌症杂志, 2011, 21(1): 46-51. DOI: 10.3969/j.issn.1007-3969.2011.01.009. [85] VINCENT A, HERMAN J, SCHULICK R, et al. Pancreatic cancer[J]. Lancet, 2011, 378(9791): 607-620. DOI: 10.1016/S0140-6736(10)62307-0. [86] KHORANA AA, MANGU PB, BERLIN J, et al. Potentially curable pancreatic cancer: american society of clinical oncology clinical practice guideline update[J]. J Clin Oncol, 2017, 35(20): 2324-2328. DOI: 10.1200/JCO.2017.72.4948. [87] BERGER AC, GARCIA M Jr, HOFFMAN JP, et al. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704[J]. J Clin Oncol, 2008, 26(36): 5918-5922. DOI: 10.1200/JCO.2008.18.6288. [88] CHEN Y, WANG XL, WANG JH, et al. Transarterial infusion with gemcitabine and oxaliplatin for the treatment of unresectable pancreatic cancer[J]. Anticancer Drugs, 2014, 25(8): 958-963. DOI: 10.1097/CAD.0000000000000120. [89] HUANG M, FEI Y, YANG YS, et al. Transarterial infusion chemotherapy of gemcitabine for the management of advanced pancreatic carcinoma[J]. West China Med J, 2004, 19(3): 373-375. DOI: 10.3969/j.issn.1002-0179.2004.03.012.黄明, 飞勇, 杨银山, 等. 经动脉灌注健择治疗中晚期胰腺癌临床疗效观察[J]. 华西医学, 2004, 19(3): 373-375. DOI: 10.3969/j.issn.1002-0179.2004.03.012. [90] RYAN DP, HONG TS, BARDEESY N. Pancreatic adenocarcinoma[J]. N Engl J Med, 2014, 371(11): 1039-1049. DOI: 10.1056/NEJMra1404198 -
本文二维码
图(2) / 表(7)
计量
- 文章访问数: 798
- HTML全文浏览量: 171
- PDF下载量: 193
- 被引次数: 0
